Holen Sie sich die Stockscreener-App
37.00
0.51%
-0.19
Schlusskurs vom Vortag:
$37.19
Offen:
$36.93
24-Stunden-Volumen:
920.05K
Relative Volume:
0.77
Marktkapitalisierung:
$2.21B
Einnahmen:
$66.05M
Nettoeinkommen (Verlust:
$-422.60M
KGV:
-5.1027
EPS:
-7.251
Netto-Cashflow:
$-384.73M
1W Leistung:
+6.02%
1M Leistung:
+13.57%
6M Leistung:
+46.13%
1J Leistung:
-14.61%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$35.02
$37.74
52-Wochen-Spanne:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
37.00 | 2.21B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-20 | Bestätigt | H.C. Wainwright | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line - Zacks Investment Research
Four FDA Decisions in Two Weeks: GSK's Hepatitis B Drug Leads the Pack as Inovio Shares Have Already Fallen Over 40% This Year - BigGo Finance
Why Did Agios Pharmaceuticals (NASDAQ:AGIO) Rise 7.41% Before a November 1 FDA Decision on Mitapivat in Sickle Cell Disease? - kalkine.ca
GSK, INO, AGIO And Sun Pharma Await Key FDA Rulings In October That Could Shape Their Drug Pipelines - Stocktwits
GlaxoSmithKline (GSK.US), Inovio (INO.US), and Agios (AGIO.US) are among a cluster of companies awaiting review, as U.S. innovative drugs enter an FDA approval window. - Moomoo
Why Is AGIO Stock Falling Today? - Stocktwits
Danaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock? - Zacks Investment Research
Cantor Fitzgerald reiterates Agios Pharma stock rating ahead of PDUFA By Investing.com - Investing.com South Africa
4 High-Risk Stocks Built for Big Returns - The Motley Fool
Agios Pharmaceuticals (AGIO) Stock Looks Fully Priced Against Current Sales - Yahoo Finance
Agios Pharmaceuticals (AGIO) Could Be 28% Undervalued Following Its November Results Call Date - Yahoo Finance
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - Zacks Investment Research
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know - TradingView
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Zacks Investment Research
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion - Yahoo Finance
Agios Pharmaceuticals, Inc. (AGIO) Investor Outlook: A 36% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
AGIO Maintained by B of A Securities -- Price Target Raised to $50 - GuruFocus
AGIOS PHARMACEUTICALS, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $50 FROM $46 - Bitget
Agios Pharmaceuticals Stock (AGIO) Opinions on Trading Strategies - Quiver Quantitative
Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily
Bank of America Corp DE Sells 31,441 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel (NASDAQ:AGIO) - Seeking Alpha
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate - Moomoo
Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes - Sahm
612,850 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by SCS Capital Management LLC - MarketBeat
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Agios Pharmaceuticals, Inc. (AGIO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Analysts Conflicted on These Healthcare Names: GE Healthcare Technologies Inc (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO) - The Globe and Mail
Q4 2025 Agios Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Agios Pharmaceuticals, Inc. (AGIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Agios Pharmaceuticals (AGIO) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Agios Pharmaceuticals, Inc. (AGIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sei Investments Co. Acquires 49,198 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Responsive Playbooks and the AGIO Inflection - Stock Traders Daily
FARALLON CAPITAL MANAGEMENT LLC Adds to Agios Pharmaceuticals In - GuruFocus
Agios Pharmaceuticals (AGIO) In Focus On Earnings As Undervalued Narrative Holds - Sahm
AGIO Maintained by JP Morgan -- Price Target Raised to $34 - GuruFocus
Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Raised to $34.00 at JPMorgan Chase & Co. - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Agios Pharmaceuticals, Inc. (AGIO) And Encourages Investors to Connect - ACCESS Newswire
Agios Pharmaceuticals (AGIO) Chief Medical Officer Sarah Gheuens Sells 30,000 Shares - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Agios Pharmaceuticals, Inc. (AGIO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 30,000 Shares - MarketBeat
Agios Pharmaceuticals (AGIO) CMO sells 30,000 shares in plan trade - Stock Titan
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - simplywall.st
How Surging Revenue With Ongoing Losses Will Impact Agios Pharmaceuticals (AGIO) Investors - webull.com
AGIO (NASDAQ: AGIO) insider Sarah Gheuens files to sell 30,000 shares - stocktitan.net
Dimensional Fund Advisors LP Increases Position in Agios Pharmaceuticals, Inc. $AGIO - marketbeat.com
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer |
Oct 22 '26 |
Option Exercise |
25.01 |
500 |
12,505 |
55,145 |
| SARAH GHEUENS | Officer |
Oct 22 '26 |
Proposed Sale |
37.52 |
500 |
18,760 |
0 |
| Gheuens Sarah | Chief Medical Officer |
Oct 22 '26 |
Sale |
37.52 |
500 |
18,760 |
54,645 |
| SARAH GHEUENS | Officer |
Oct 21 '26 |
Proposed Sale |
37.53 |
1,489 |
55,881 |
0 |
| Gheuens Sarah | Chief Medical Officer |
Oct 21 '26 |
Sale |
37.53 |
1,489 |
55,882 |
54,645 |
| SARAH GHEUENS | Officer |
Aug 04 '26 |
Proposed Sale |
30.48 |
30,000 |
914,283 |
0 |
| Gheuens Sarah | Chief Medical Officer |
Aug 04 '26 |
Sale |
30.48 |
30,000 |
914,400 |
54,645 |
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
8,375 |
0 |
88,652 |
| Gheuens Sarah | Chief Medical Officer |
Jul 01 '26 |
Sale |
37.56 |
4,007 |
150,503 |
84,645 |
| Gheuens Sarah | Officer |
Jul 01 '26 |
Proposed Sale |
37.56 |
4,007 |
150,503 |
0 |
2.38%
3.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):